Health
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19 – GlobeNewswire
Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
CALGARY, Alberta, March 03, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) and QIMR Berghofer Medical Research Institute (QIMR Berghofer), one of Australias most successful medical research institutes, announced today the publishing of a new article providing evidence of apabetalones potential benefit on SARS-CoV-2 (COVID-19). The article, titled: Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical),…
-
General24 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
Noosa News22 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
Noosa News24 hours agoMeasles alert issued across popular south-east attractions
-
General18 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts